We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+24.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$498M
AUM Growth
+$258M
Cap. Flow
+$49.1M
Cap. Flow %
9.86%
Top 10 Hldgs %
69.52%
Holding
145
New
57
Increased
20
Reduced
22
Closed
41

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$31.2M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$6.99M
3
MRNA icon
Moderna
MRNA
+$3.94M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$3.78M
5
MTVA
MetaVia Inc
MTVA
+$3.18M

Top Sells

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$2.89M
2
ENLV icon
Enlivex Ltd
ENLV
+$2.31M
3
NOVN
Novan, Inc. Common Stock
NOVN
+$2.11M
4
OTLK icon
Outlook Therapeutics
OTLK
+$1.94M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$1.78M

Sector Composition

Rank Sector Weight
1 Healthcare 11.32%
2 Industrials 0.26%
3 Technology 0.12%
4 Consumer Discretionary 0.09%
5 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QCLS
126
Q/C Technologies Inc
QCLS
$22.3M
– –
-9
Closed -$118K
SEEL
127
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
-132
Closed -$249K
ASXC
128
DELISTED
Asensus Surgical, Inc.
ASXC
– –
-1,760,262
Closed -$850K
NURO
129
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
– –
-10,281
Closed -$93K
DMK
130
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
– –
-1,260
Closed -$32K
CYTO
131
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-224
Closed -$72K
NOVN
132
DELISTED
Novan, Inc. Common Stock
NOVN
– –
-443,816
Closed -$2.11M
BLCM
133
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-18,927
Closed -$89K
SRNE
134
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-287,386
Closed -$1.1M
PTE
135
DELISTED
PolarityTE, Inc. Common Stock
PTE
– –
-13,974
Closed -$371K
SHIPZ
136
DELISTED
Seanergy Maritime Holdings Corp Class B Warrant
SHIPZ
– –
-897,499
Closed -$45K
ZSAN
137
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-5,815
Closed -$114K
BXRX
138
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
– –
-267
Closed -$1.28M
TRIL
139
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-287,906
Closed -$1.78M
NBRV
140
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-1,470
Closed -$211K
TTPH
141
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-667,000
Closed -$854K
RBZ
142
DELISTED
Reebonz Holding Limited Ordinary Shares
RBZ
– –
-25,000
Closed -$10K
NVIV
143
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
– –
-1,306
Closed -$55K
OIL
144
CALL
DELISTED
iPath Series B S&P GSCI Crude Oil ETN
OIL
– –
-250
Closed -$1.16M
2 3 4 5
6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2020 Portfolio in Review

As of Q2 2020, Sabby Management held 145 positions worth $498M, up 107% from $241M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management deployed $49.1M of net new capital in Q2 2020, opening 57 new positions and adding to 20 existing holdings. Its largest new stake was Biogen: 103,902 shares worth $27.8M.

By sector, the portfolio is most concentrated in Healthcare at 11% of assets, up from 7.3% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Enlivex Ltd, an estimated $2.31M trimmed.

  • Sabby Management's largest Q2 2020 buy was Biogen: 103,902 shares worth $27.8M.
  • Sabby Management added most to State Street Health Care Select Sector SPDR ETF in Q2 2020, an estimated $6.99M increase.
  • Sabby Management's biggest Q2 2020 reduction was Enlivex Ltd, cutting an estimated $2.31M.
  • Sabby Management fully exited SPDR Gold Trust in Q2 2020, selling an estimated $2.89M.
  • Sabby Management's ten largest holdings make up 70% of its $498M portfolio in Q2 2020.
  • Sabby Management opened 57 new positions and closed 41 in Q2 2020.
  • Sabby Management's portfolio value rose 107% quarter-over-quarter to $498M.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.